Validation of a new fibrinolysis assay for thrombelastometry on the ROTEM® device
Recruiting
- Conditions
- Sepsis (with/without DIC), Liver impairment (Child-Pugh A/B/C), Patientgroups in which an altered hemostatic balance can be expected, like patients treated for hematological malignancies who have severe thrombocytopenia
- Registration Number
- NL-OMON21605
- Lead Sponsor
- MUMC+
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 200
Inclusion Criteria
The population consist of all in hospital adult (= 18 years old) patients at the Maastricht University Medical Centre. 20-30 patients of each group will be asked informed consent for blood withdrawal for this in vitro measurement on the ROTEM® device.
The population consist of the following patient groups:
- Sepsis (with/without DIC)
- Liver impairment (Child-Pugh A/B/C)
- Patientgroups in which an altered hemostatic balance can be expected, like patients treated for hematological malignancies who have severe thrombocytopenia
Exclusion Criteria
temperature >38,0°C, sepsis, active bleeding, splenomegaly or use of anticoagulation medication.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Validation of a newly developed fibrinolysis assay on the ROTEM® device in multiple groups of patients with different pathological entities.
- Secondary Outcome Measures
Name Time Method Effects of platelet transfusion on fibrinolysis assays in chemotherapy induced thrombocytopenic patients